Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Blogs/Articles, Rare diseases
Mitigating Risks in Early Access Programs: A Guide for Biotech Companies
Thought Leadership, Rare diseases
Leveraging Early Access Programs and Real-World Data for commercial success
Blogs/Articles, Rare diseases
Orphan drugs: How to avoid costly stock losses in Europe
Blogs/Articles, Rare diseases
Out-licensing vs partnering: Strategies for accessing Europe
Blogs/Articles, Rare diseases
Is data drought holding back your orphan drug?
Thought Leadership, Rare diseases
Market access for orphan drugs in Switzerland: a guide for US Biotechs
Blogs/Articles, Rare diseases
An introduction to PASS studies
Thought Leadership, Rare diseases
The impact of real-world data in gaining access to the European orphan drugs market.
News, Rare diseases
Sciensus partners with ITN and Genetic Alliance UK for Rare Disease Day